BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

January 20, 2014 8:00 AM UTC

Celltrion Inc. (KOSDAQ:068270) lost W350 to W45,650 last week after South Korea's Ministry of Food and Drug Safety (MFDS) approved Herzuma trastuzumab as a biosimilar of Herceptin trastuzumab to treat early and advanced HER2-positive breast cancer and advanced stomach cancer.

Herzuma is the first approved biosimilar of Herceptin in Korea. Celltrion said it plans to launch Herzuma this half...